{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:54:12Z","timestamp":1789419252318,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T00:00:00Z","timestamp":1533686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Rochester Epidemiology Project"},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG034676"],"award-info":[{"award-number":["R01AG034676"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical and Translational Science Awards","award":["UL1 TR000135"],"award-info":[{"award-number":["UL1 TR000135"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>True population-based clinical and outcomes data are lacking for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis (AAGN). Therefore we aimed to estimate the incidence, prevalence and mortality of AAGN, as well as the relationship between the grade of chronic renal damage at presentation and renal and non-renal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with AAGN were identified among a population-based incident cohort of 57 Olmsted County residents diagnosed with ANCA-associated vasculitis (AAV) in 1996\u20132015. Incidence rates were age and sex adjusted to the 2010 US white population. Age- and sex-adjusted prevalence was calculated for 1 January 2015. Survival rates were compared with expected rates in the Minnesota population. Chronic renal damage was assessed by chronicity score (CS) on biopsies performed at diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-four (60%) patients had AAGN. Of these, 65% had microscopic polyangiitis (MPA) and 74% were myeloperoxidase (MPO)-ANCA positive. The annual incidence of AAGN was 2.0\/100\u2009000 population [95% confidence interval (CI) 1.3\u20132.7] and the overall prevalence was 35\/100\u2009000 (95% CI 24\u201347). Mortality for AAGN was increased (P\u2009&amp;lt;\u20090.001), whereas mortality for AAV without glomerulonephritis did not differ from the general population. Minimal to mild CS predicted recovery of renal function at 1\u2009year; clinical diagnosis (granulomatosis with polyangiitis versus MPA) and ANCA specificity (proteinase 3 versus MPO) did not. This observation was replicated in an independent cohort of 38 newly diagnosed AAGN patients seen at our centre over the 1999\u20132014 period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The annual incidence and prevalence of AAGN in Minnesota are 2.0\/100\u2009000 and 35\/100\u2009000, respectively. Mortality is worse compared with AAV patients without glomerulonephritis. More advanced renal damage at diagnosis predicts less renal recovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfy250","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T11:43:06Z","timestamp":1531222986000},"page":"1508-1517","source":"Crossref","is-referenced-by-count":66,"title":["Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort"],"prefix":"10.1093","volume":"34","author":[{"given":"Alvise","family":"Berti","sequence":"first","affiliation":[{"name":"Immunology, Rheumatology, Allergy and Rare Diseases Department, San Raffaele Scientific Institute, Milan, Italy"},{"name":"Rheumatology Unit, Santa Chiara Hospital, Trento, Italy"},{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Cornec-Le Gall","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA"},{"name":"INSERM UMR1078, G\u00e9n\u00e9tique, G\u00e9nomique Fonctionnelle et Biotechnologies, Universit\u00e9 de Brest, Service de N\u00e9phrologie, CHU de Brest, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA"},{"name":"INSERM UMR1227, Lymphocytes B et Autoimmunit\u00e9, Universit\u00e9 de Bretagne Occidentale, Service de Rhumatologie et Centre National de R\u00e9f\u00e9rence des maladies auto-immunes syst\u00e9miques rares CERAINO, CHU de Brest, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Casal Moura","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L","family":"Matteson","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA"},{"name":"Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S","family":"Crowson","sequence":"first","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, USA"},{"name":"Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Ravindran","sequence":"first","affiliation":[{"name":"Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sethi","sequence":"first","affiliation":[{"name":"Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C","family":"Fervenza","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Specks","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,8]]},"reference":[{"key":"2020070205440148200_gfy250-B1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2012.08.006","article-title":"Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis","volume":"12","author":"Sinico","year":"2013","journal-title":"Autoimmun Rev"},{"key":"2020070205440148200_gfy250-B2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"de Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B3","first-page":"2338","article-title":"The epidemiology of ANCA associated vasculitis in Olmsted County, Minnesota (USA): a 20 year population-based study","volume-title":"Arthritis Rheumatol","author":"Berti","year":"2017"},{"key":"2020070205440148200_gfy250-B4","first-page":"i37","article-title":"Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn","volume":"32","author":"Cornec","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205440148200_gfy250-B5","first-page":"1560","article-title":"Incidence and survival rates in Wegener\u2019s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa","volume-title":"Rheumatology (Oxford)","author":"Mohammad","year":"2009"},{"key":"2020070205440148200_gfy250-B6","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3899\/jrheum.131038","article-title":"A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis","volume":"41","author":"Mohammad","year":"2014","journal-title":"J Rheumatol"},{"key":"2020070205440148200_gfy250-B7","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1093\/ndt\/gfn354","article-title":"Renal vasculitis in Japan and the UK\u2013are there differences in epidemiology and clinical phenotype?","volume":"23","author":"Watts","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205440148200_gfy250-B8","first-page":"i23","article-title":"Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden","volume":"30","author":"Mohammad","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205440148200_gfy250-B9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2215\/CJN.01461005","article-title":"Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan","volume":"1","author":"Fujimoto","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B10","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1681\/ASN.2014090903","article-title":"Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis","volume":"26","author":"Hilhorst","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B11","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ndt\/gfu084","article-title":"ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis","volume":"29","author":"Quintana","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205440148200_gfy250-B12","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B14","first-page":"S105","article-title":"The relation between histopathological classification and renal outcome, ANCA subtype and treatment regimens in ANCA-associated vasculitis","volume":"34","author":"Kristensen","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2020070205440148200_gfy250-B15","first-page":"56","article-title":"Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature","volume":"33","author":"Moroni","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2020070205440148200_gfy250-B16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.kint.2017.01.002","article-title":"A proposal for standardized grading of chronic changes in native kidney biopsy specimens","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"key":"2020070205440148200_gfy250-B17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/aje\/kwq482","article-title":"Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project","volume":"173","author":"St Sauver","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2020070205440148200_gfy250-B18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mayocp.2011.11.009","article-title":"Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project","volume":"87","author":"St Sauver","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"2020070205440148200_gfy250-B19","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2020070205440148200_gfy250-B20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0197-2456(02)00209-X","article-title":"WGET Research Group. Design of the Wegener\u2019s Granulomatosis Etanercept Trial (WGET)","volume":"23","year":"2002","journal-title":"Control Clin Trials"},{"key":"2020070205440148200_gfy250-B21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2020070205440148200_gfy250-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2020070205440148200_gfy250-B23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2020070205440148200_gfy250-B24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2020070205440148200_gfy250-B25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"2020070205440148200_gfy250-B26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2020070205440148200_gfy250-B27","first-page":"S1","article-title":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2020070205440148200_gfy250-B28","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"30","author":"Watts","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205440148200_gfy250-B29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ndt\/15.10.1593","article-title":"Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study","volume":"15","author":"Hedger","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"2020070205440148200_gfy250-B30","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2020070205440148200_gfy250-B31","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.24544","article-title":"Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database","volume":"61","author":"Watts","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020070205440148200_gfy250-B32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/ard.60.2.170","article-title":"Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2020070205440148200_gfy250-B33","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","article-title":"Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2020070205440148200_gfy250-B34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine"},{"key":"2020070205440148200_gfy250-B35","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1681\/ASN.2005080870","article-title":"Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement","volume":"17","author":"de Lind van Wijngaarden","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"2020070205440148200_gfy250-B37","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2215\/CJN.07910814","article-title":"Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis","volume":"10","author":"Chen","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B38","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2009.10.047","article-title":"Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine","volume":"55","author":"Day","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2020070205440148200_gfy250-B39","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2215\/CJN.00120115","article-title":"Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis","volume":"10","author":"Manenti","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B40","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1046\/j.1523-1755.2002.00605.x","article-title":"Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients","volume":"62","author":"Hauer","year":"2002","journal-title":"Kidney Int"},{"key":"2020070205440148200_gfy250-B41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3899\/jrheum.160866","article-title":"Histopathological classification and renal outcome in patients with antineutrophil cytoplasmic antibodies-associated renal vasculitis: a study of 186 patients and metaanalysis","volume":"44","author":"Chen","year":"2017","journal-title":"J Rheumatol"},{"key":"2020070205440148200_gfy250-B42","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2215\/CJN.04800516","article-title":"Prognostic value of histologic classification of ANCA-associated glomerulonephritis","volume":"11","author":"Bjorneklett","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B43","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.ajkd.2013.08.025","article-title":"Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis","volume":"63","author":"Ford","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2020070205440148200_gfy250-B44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1681\/ASN.2011040330","article-title":"Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy","volume":"23","author":"Berden","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","article-title":"Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis","volume":"147","author":"Finkielman","year":"2007","journal-title":"Ann Intern Med"},{"key":"2020070205440148200_gfy250-B46","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/pds.4116","article-title":"Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases","volume":"25","author":"Sreih","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020070205440148200_gfy250-B47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1681\/ASN.2006091021","article-title":"Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis","volume":"18","author":"Chen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2020070205440148200_gfy250-B48","doi-asserted-by":"crossref","first-page":"i139","DOI":"10.1093\/ndt\/gfw299","article-title":"Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis","volume":"32","author":"Sethi","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/9\/1508\/33455973\/gfy250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/9\/1508\/33455973\/gfy250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T05:44:46Z","timestamp":1593668686000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/9\/1508\/5068231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,8]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,8,8]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy250","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733808728.793555960","asserted-by":"object"}]},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2018,8,8]]}}}